Protagonist Therapeutics Inc [PTGX] stock prices are down -0.10% to $38.49 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The PTGX shares have gain 2.86% over the last week, with a monthly amount glided 1.02%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Protagonist Therapeutics Inc [NASDAQ: PTGX] stock has seen the most recent analyst activity on December 06, 2024, when Goldman initiated its Neutral rating and assigned the stock a price target of $47. Previously, BMO Capital Markets started tracking the stock with Outperform rating on December 06, 2024, and set its price target to $62. On November 05, 2024, Wedbush initiated with a Outperform rating and assigned a price target of $58 on the stock. TD Cowen started tracking the stock assigning a Buy rating and suggested a price target of $65 on September 24, 2024. Truist initiated its recommendation with a Buy and recommended $60 as its price target on September 09, 2024. CapitalOne started tracking with a Overweight rating for this stock on October 30, 2023, and assigned it a price target of $32.
The stock price of Protagonist Therapeutics Inc [PTGX] has been fluctuating between $24.22 and $48.89 over the past year. Currently, Wall Street analysts expect the stock to reach $57.33 within the next 12 months. Protagonist Therapeutics Inc [NASDAQ: PTGX] shares were valued at $38.49 at the most recent close of the market. An investor can expect a potential return of 48.95% based on the average PTGX price forecast.
Analyzing the PTGX fundamentals
Gross Profit Margin for this corporation currently stands at 0.99% with Operating Profit Margin at 0.46%, Pretax Profit Margin comes in at 0.53%, and Net Profit Margin reading is 0.53%. To continue investigating profitability, this company’s Return on Assets is posted at 0.28, Equity is 0.35 and Total Capital is 0.27. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 37.86 points at the first support level, and at 37.22 for the second support level. However, for the 1st resistance point, the stock is sitting at 39.10, and for the 2nd resistance point, it is at 39.70.
Ratios To Look Out For
It’s worth pointing out that Protagonist Therapeutics Inc [NASDAQ:PTGX]’s Current Ratio is 10.70. Further, the Quick Ratio stands at 10.70, while the Cash Ratio is 2.94. Considering the valuation of this stock, the price to sales ratio is 7.08, the price to book ratio is 4.31 and price to earnings (TTM) ratio is 14.44.
Transactions by insiders
Recent insider trading involved PATEL DINESH V PH D, President and CEO, that happened on Feb 19 ’25 when 5359.0 shares were sold. Chief Medical Officer, MOLINA ARTURO MD completed a deal on Nov 27 ’24 to sell 26000.0 shares. Meanwhile, Chief Medical Officer MOLINA ARTURO MD sold 5529.0 shares on Nov 26 ’24.
